The story of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in income, its exclusivity period created a deluge of knock-off medications, significantly diminishing its dominance. While some pharmaceutical companies may try to capitalize on related treatments , the